Alprolix is administered intravenously as an infusion [1].
How is Alprolix given to patients?
Alprolix, a recombinant Factor IX Fc fusion protein, is delivered through an intravenous (IV) infusion [1][2]. This method ensures the medication enters the bloodstream directly, allowing it to circulate and facilitate blood clotting [1].
What is Alprolix used for?
Alprolix is a treatment for adults and children with Hemophilia B [1]. It helps to reduce the frequency of bleeding episodes [1][2].
How does Alprolix work?
Alprolix works by replacing the deficient Factor IX protein in individuals with Hemophilia B [1][2]. The fusion of Factor IX with the Fc portion of immunoglobulin G extends its half-life, meaning it stays in the body longer and requires less frequent infusions compared to conventional Factor IX therapies [2].
What are the potential side effects of Alprolix?
Common side effects associated with Alprolix include infusion site reactions, headache, and fever [1]. Allergic reactions, including rash and hives, are also possible [1]. Patients may develop inhibitors to Factor IX, which are antibodies that can interfere with the effectiveness of the treatment [1].
How long does Alprolix infusion take?
The duration of an Alprolix infusion typically takes approximately 5 minutes [1].
When does Alprolix patent expire?
Information regarding specific patent expiry dates for Alprolix can be found on resources like DrugPatentWatch.com [3]. Patent information is crucial for understanding when generic or biosimilar versions of a drug might become available.